Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Liabilities and Shareholders Equity (2018 - 2025)

Historic Liabilities and Shareholders Equity for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $287.8 million.

  • Neurogene's Liabilities and Shareholders Equity rose 7537.9% to $287.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 6225.67%. This contributed to the annual value of $335.7 million for FY2024, which is 5084.04% up from last year.
  • Neurogene's Liabilities and Shareholders Equity amounted to $287.8 million in Q3 2025, which was up 7537.9% from $297.3 million recorded in Q2 2025.
  • Neurogene's Liabilities and Shareholders Equity's 5-year high stood at $335.7 million during Q4 2024, with a 5-year trough of $89.6 million in Q3 2023.
  • For the 3-year period, Neurogene's Liabilities and Shareholders Equity averaged around $207.3 million, with its median value being $195.4 million (2024).
  • Over the last 5 years, Neurogene's Liabilities and Shareholders Equity had its largest YoY gain of 9840.54% in 2024, and its largest YoY loss of 5084.04% in 2024.
  • Quarter analysis of 3 years shows Neurogene's Liabilities and Shareholders Equity stood at $222.6 million in 2023, then surged by 50.84% to $335.7 million in 2024, then fell by 14.27% to $287.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $287.8 million in Q3 2025, compared to $297.3 million in Q2 2025 and $315.3 million in Q1 2025.